{
    "clinical_study": {
        "@rank": "36642", 
        "arm_group": {
            "arm_group_label": "Hypercholesterolemic patients", 
            "description": "Hypercholesterolemic Patients with documented CAD and poor- or non responders or intolerant to pharmacological treatment (statins) on chronic LDL-apheresis treatment"
        }, 
        "biospec_descr": {
            "textblock": "serum and plasma"
        }, 
        "biospec_retention": "Samples Without DNA", 
        "brief_summary": {
            "textblock": "Inflammation plays a major role in atherosclerosis. Pentraxin 3 (PTX3) a multifunctional\n      pattern-recognition protein, is expressed in many tissues/cells, including innate immunity\n      cells, endothelium and atherosclerotic plaques. Its role is controversial: it may exert\n      protective cardiovascular effects and/or it may be an indicator of plaque vulnerability and\n      future cardiovascular risk.\n\n      LDL-Apheresis removes apoB100-containing lipoproteins and it can prevent progression of\n      coronary artery disease (CAD). LDL-Apheresis exerts non-lipidic beneficial effects on the\n      procoagulatory state and on hemorheology. No data exist about the effects of LDL-Apheresis\n      on plasma PTX3 levels."
        }, 
        "brief_title": "Effect of LDL-apheresis on PTX3 Plasma Levels in Hypercholesterolemic Patients", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Hypercholesterolemia", 
        "condition_browse": {
            "mesh_term": [
                "Coronary Artery Disease", 
                "Myocardial Ischemia", 
                "Coronary Disease", 
                "Hypercholesterolemia"
            ]
        }, 
        "detailed_description": {
            "textblock": "Hypercholesterolemic patients  with documented CAD, on chronic fortnightly  LDL-apheresis\n      treatment will be enrolled in this study.\n\n      Blood samples will be collected before and after a single LDL-Apheresis treatment to asses\n      PTX3, HsCRP, IL6, IL10, Fibrinogen and  lipid plasma levels."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Hypercholesterolemia\n\n          -  documented CAD\n\n          -  chronic   LDL-apheresis treatment\n\n        Exclusion Criteria:\n\n          -  mental incapacity, unwillingness or language barriers precluding adequate\n             understanding or cooperation"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Hypercholesterolemic patients  with documented CAD, on cronic fortnightly  HELP-apheresis\n        treatment."
            }
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 24, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01678521", 
            "org_study_id": "MZentiPTX3"
        }, 
        "intervention": {
            "arm_group_label": "Hypercholesterolemic patients", 
            "description": "The acronym H.E.L.P. stands for Heparin-induced Extracorporeal Low-density-lipoprotein Precipitation. Antecubital veins served as blood access. The mean blood volume processed per session is of approximately 3000 ml.", 
            "intervention_name": "LDL-apheresis", 
            "intervention_type": "Procedure", 
            "other_name": "HELP-apheresis"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Hypercholesterolemia", 
            "LDL-apheresis", 
            "Coronary artery disease", 
            "PTX3", 
            "CRP", 
            "IL6", 
            "IL10"
        ], 
        "lastchanged_date": "September 7, 2012", 
        "location": {
            "contact": {
                "email": "mariagrazia.zenti@univr.it", 
                "last_name": "Maria Grazia Zenti, MD", 
                "phone": "+390458123110"
            }, 
            "contact_backup": {
                "email": "riccardo.bonadonna@univr.it", 
                "last_name": "Riccardo C Bonadonna, MD,PHD", 
                "phone": "+390458123115"
            }, 
            "facility": {
                "address": {
                    "city": "Verona", 
                    "country": "Italy", 
                    "state": "piazzale Stefani1", 
                    "zip": "37126"
                }, 
                "name": "Endocrinologia e Malattie Metaboliche, Azienda Ospedaliera Universitaria Integrata Verona"
            }, 
            "investigator": {
                "last_name": "Maria Grazia Zenti, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_groups": "1", 
        "official_title": "Effect of LDL-apheresis on Pentraxin3 Plasma Levels in Hypercholesterolemic Patients With Coronary Artery Disease", 
        "overall_contact": {
            "email": "mariagrazia.zenti@univr.it", 
            "last_name": "Maria Grazia Zenti, MD", 
            "phone": "+390458123110"
        }, 
        "overall_contact_backup": {
            "email": "riccardo.bonadonna@univr.it", 
            "last_name": "Riccardo C Bonadonna, MD, PHD", 
            "phone": "+390458123115"
        }, 
        "overall_official": {
            "affiliation": "Universita di Verona", 
            "last_name": "Enzo Bonora, Professor", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Italy: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "blood samples will be collected before and after a single LDL-apheresis treatment", 
            "measure": "acute change in PTX3 plasma values", 
            "safety_issue": "No", 
            "time_frame": "before and at the end of one LDL-apheresis treatment (about 6 hours)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01678521"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Universita di Verona", 
            "investigator_full_name": "Maria Grazia Zenti", 
            "investigator_title": "principal investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "blood samples will be collected before and after a single LDL-apheresis treatment", 
                "measure": "acute change in hsCRP", 
                "safety_issue": "No", 
                "time_frame": "before and at the end of one LDL-apheresis treatment (about 6 hours)"
            }, 
            {
                "description": "blood samples will be collected before and after a single LDL-apheresis treatment", 
                "measure": "acute change in IL6 and IL10", 
                "safety_issue": "No", 
                "time_frame": "before and at the end of one LDL-apheresis treatment (about 6 hours)"
            }
        ], 
        "source": "Universita di Verona", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Universita di Verona", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "September 2012"
    }
}